ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Ju, Bin; Zhang, Qi; Ge, Jiwan; Wang, Ruoke; Sun, Jing; Ge, Xiangyang; Yu, Jiazhen; Shan, Sisi; Zhou, Bing; Song, Shuo; Tang, Xian; Yu, Jinfang; Lan, Jun; Yuan, Jing; Wang, Haiyan; Zhao, Juanjuan; Zhang, Shuye; Wang, Youchun; Shi, Xuanling; Liu, Lei; Zhao, Jincun; Wang, Xinquan*; Zhang, Zheng*; Zhang, Linqi*复旦大学; 广州医学院; 清华大学; 1
Nature2020-8-6DOI: 10.1038/s41586-020-2380-z
6阅读
引用收藏
分享

摘要

The coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents a global health emergency that is in urgent need of intervention(1-3). The entry of SARS-CoV-2 into its target cells depends on binding between the receptor-binding domain (RBD) of the viral spike protein and its cellular receptor, angiotensin-converting enzyme 2 (ACE2)(2,4-6). Here we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells from 8 individuals infected with SARS-CoV-2. We identified antibodies that potently neutralize SARS-CoV-2; this activity correlates with competition with ACE2 for binding to RBD. Unexpectedly, the anti-SARS-CoV-2 antibodies and the infected plasma did not cross-react with the RBDs of SARS-CoV or Middle East respiratory syndrome-related coronavirus (MERS-CoV), although there was substantial plasma cross-reactivity to their trimeric spike proteins. Analysis of the crystal structure of RBD-bound antibody revealed that steric hindrance inhibits viral engagement with ACE2, thereby blocking viral entry. These findings suggest that anti-RBD antibodies are largely viral-species-specific inhibitors. The antibodies identified here may be candidates for development of clinical interventions against SARS-CoV-2. @@@ In a study of antibodies isolated from patients infected with SARS-CoV-2, antibodies that potently neutralized the virus competed with angiotensin-converting enzyme 2 for binding to the receptor-binding domain of the viral spike protein, suggesting that antibodies that disrupt this interaction could be developed to treat SARS-CoV-2 infection.

学科与关键词

关键词
SARS CORONAVIRUSSPIKE PROTEINCOVVACCINEBINDING
相关
加载中…
  • Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
    Ge, Jiwan; Wang, Ruoke; Ju, Bin; Zhang, Qi; Sun, Jing; Chen, Peng; Zhang, Senyan; Tian, Yuling; Shan, Sisi; Cheng, Lin; Zhou, Bing; Song, Shuo; Zhao, Juanjuan; Wang, Haiyan; Shi, Xuanling; Ding, Qiang; Liu, Lei; Zhao, Jincun; Zhang, Zheng*; Wang, Xinquan*; Zhang, Linqi*Nature Communications, 2021, 12(1): 250.被引 79
  • Perspectives on the development of neutralizing antibodies against SARS-CoV-2
    Mitchell, HoAntibody Therapeutics, 2020, 3(2): 109-114.被引 7
  • A humanized neutralizing antibody against MERS-CoV targeting the receptor-binding domain of the spike protein
    Li, Yan; Wan, Yuhua; Liu, Peipei; Zhao, Jincun; Lu, Guangwen; Qi, Jianxun; Wang, Qihui; Lu, Xuancheng; Wu, Ying; Liu, Wenjun; Zhang, Buchang; Yuen, Kwok-Yung; Perlman, Stanley; Gao, George F.; Yan, Jinghua*Cell Research, 2015, 25(11): 1237-1249.被引 112
查看全部 →

发表信息

论文状态
公开发表
期刊
Nature
发表日期
2020-08-06
卷期
第 584 卷, 第 7819 期
页码
115-+
DOI
10.1038/s41586-020-2380-z
语言
ENGLISH
期刊收录
NSL.NATURE-INDEX.SCIE
期刊等级
1区
成果收录
SCIE · PUBMED
资助标注
Bill & Melinda Gates Foundation; Science and Technology Innovation Committee of Shenzhen Municipality [202002073000002]; Tsinghua University Initiative Scientific Research Program [20201080053]; National Beijing Municipal Science and Technology Commission [171100000517-001, 171100000517-003]; Beijing Advanced Innovation Center for Structural Biology at Tsinghua University; National Key Plan for Scientific Research and Development of China [2016YFD0500307]; Tencent Foundation; Shuidi Foundation; TH Capital

作者

  • J

    Ju, Bin (第一作者)

    shenzhen third peoples hosp · 2

  • Z

    Zhang, Qi

    tsinghua univ

查看全部 24 位作者收起作者
  • G

    Ge, Jiwan

    tsinghua univ

  • W

    Wang, Ruoke

    tsinghua univ

  • S

    Sun, Jing

    1 · guangzhou med univ

  • G

    Ge, Xiangyang

    shenzhen third peoples hosp

  • Y

    Yu, Jiazhen

    shenzhen third peoples hosp

  • S

    Shan, Sisi

    tsinghua univ

  • Z

    Zhou, Bing

    shenzhen third peoples hosp

  • S

    Song, Shuo

    shenzhen third peoples hosp

  • T

    Tang, Xian

    shenzhen third peoples hosp

  • Y

    Yu, Jinfang

    tsinghua univ

  • L

    Lan, Jun

    tsinghua univ

  • Y

    Yuan, Jing

    shenzhen third peoples hosp

  • W

    Wang, Haiyan

    shenzhen third peoples hosp

  • Z

    Zhao, Juanjuan

  • Z

    Zhang, Shuye

    fudan univ

  • W

    Wang, Youchun

  • S

    Shi, Xuanling

    tsinghua univ

  • L

    Liu, Lei

    2 · shenzhen third peoples hosp

  • Z

    Zhao, Jincun

  • W

    Wang, Xinquan (通讯)

    tsinghua univ

  • Z

    Zhang, Zheng (通讯)

    2 · shenzhen third peoples hosp

  • Z

    Zhang, Linqi (通讯)

    tsinghua univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417